Literature DB >> 12642353

Drugs that induce repolarization abnormalities cause bradycardia in zebrafish.

David J Milan1, Travis A Peterson, Jeremy N Ruskin, Randall T Peterson, Calum A MacRae.   

Abstract

BACKGROUND: Drug-induced QT prolongation and torsades de pointes remain significant and often unpredictable clinical problems. Current in vitro preclinical assays are limited by biological simplicity, and in vivo models suffer from expense and low throughput. METHODS AND
RESULTS: During a screen for the effects of 100 small molecules on the heart rate of the zebrafish, Danio rerio, we found that drugs that cause QT prolongation in humans consistently caused bradycardia and AV block in the zebrafish. Of 23 such drugs tested, 18 were positive in this initial screen. Poor absorption explained 4 of 5 false-negative results, as demonstrated by microinjection. Overall, 22 of 23 compounds that cause repolarization abnormalities were positive in this assay. Antisense "knockdown" of the zebrafish KCNH2 ortholog yielded bradycardia in a dose dependent manner confirming the effects of reduction of repolarizing potassium current in this model. Classical drug-drug interactions between erythromycin and cisapride, as well as cimetidine and terfenadine, were also reproduced.
CONCLUSION: This simple high-throughput assay is a promising addition to the repertoire of preclinical tests for drug-induced repolarization abnormalities. The genetic tractability of the zebrafish will allow the exploration of heritable modifiers of such drug effects.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12642353     DOI: 10.1161/01.cir.0000061912.88753.87

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  118 in total

Review 1.  Optical mapping in the developing zebrafish heart.

Authors:  M Khaled Sabeh; Hussein Kekhia; Calum A Macrae
Journal:  Pediatr Cardiol       Date:  2012-03-30       Impact factor: 1.655

2.  Visualizing voltage dynamics in zebrafish heart.

Authors:  Hidekazu Tsutsui; Shin-ichi Higashijima; Atsushi Miyawaki; Yasushi Okamura
Journal:  J Physiol       Date:  2010-04-26       Impact factor: 5.182

3.  High-resolution cardiovascular function confirms functional orthology of myocardial contractility pathways in zebrafish.

Authors:  Jordan T Shin; Eugene V Pomerantsev; John D Mably; Calum A MacRae
Journal:  Physiol Genomics       Date:  2010-04-13       Impact factor: 3.107

4.  Screening: the age of fishes.

Authors:  Monya Baker
Journal:  Nat Methods       Date:  2011-01       Impact factor: 28.547

5.  Zebrafish as a model for cardiovascular development and disease.

Authors:  Catherine T Nguyen; Qing Lu; Yibin Wang; Jau-Nian Chen
Journal:  Drug Discov Today Dis Models       Date:  2008

Review 6.  Screening for chemicals that affect hair cell death and survival in the zebrafish lateral line.

Authors:  Henry Ou; Julian A Simon; Edwin W Rubel; David W Raible
Journal:  Hear Res       Date:  2012-01-31       Impact factor: 3.208

7.  Mass spectrometry imaging in zebrafish larvae for assessing drug safety and metabolism.

Authors:  Mariana Asslan; Nidia Lauzon; Maja Beus; Dusica Maysinger; Simon Rousseau
Journal:  Anal Bioanal Chem       Date:  2021-06-26       Impact factor: 4.142

8.  Using zebrafish to assess the impact of drugs on neural development and function.

Authors:  Su Guo
Journal:  Expert Opin Drug Discov       Date:  2009-07-01       Impact factor: 6.098

9.  An in vivo platform for rapid high-throughput antitubercular drug discovery.

Authors:  Kevin Takaki; Christine L Cosma; Mark A Troll; Lalita Ramakrishnan
Journal:  Cell Rep       Date:  2012-07-20       Impact factor: 9.423

10.  Acetyl L-carnitine targets adenosine triphosphate synthase in protecting zebrafish embryos from toxicities induced by verapamil and ketamine: An in vivo assessment.

Authors:  Xiaoqing Guo; Melanie Dumas; Bonnie L Robinson; Syed F Ali; Merle G Paule; Qiang Gu; Jyotshna Kanungo
Journal:  J Appl Toxicol       Date:  2016-05-18       Impact factor: 3.446

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.